Phillips D L
Clin Radiol. 1981 Sep;32(5):543-6. doi: 10.1016/s0009-9260(81)80184-5.
This report describes the experience of the BNLI in the treatment of localised (Stage I, II) non-Hodgkin's lymphomas (NHL). About a third of all patients with NHL presenting to collaborators in the BNLI were considered after investigation to have localised disease. This relatively large number suggests that some cases may have been understaged. Patients with Grade 1 disease were treated with either local irradiation or with local irradiation followed by chlorambucil. Survival rates in the two groups were essentially similar and it appeared that radiotherapy alone provided equally effective treatment. Patients with Grade 2 lymphomas were treated with either local irradiation or with local irradiation followed by COP. Primary nodal disease was not obviously affected by the addition of chemotherapy. Extranodal disease arising in the gut below the diaphragm appeared to be adversely affected by the irradiation which was of necessity spread over several weeks, delaying the use of chemotherapy. Extranodal disease arising in the head and neck region is controlled in about 80% of patients and the routine use of prophylactic combination chemotherapy confers no benefit to the patient.
本报告描述了英国国家淋巴瘤研究组（BNLI）治疗局限性（I期、II期）非霍奇金淋巴瘤（NHL）的经验。在向BNLI的合作机构就诊的所有NHL患者中，约三分之一经检查后被认为患有局限性疾病。这一相对较大的数字表明，一些病例可能分期过低。1级疾病患者接受局部放疗或局部放疗后加用苯丁酸氮芥治疗。两组的生存率基本相似，似乎单纯放疗提供了同样有效的治疗。2级淋巴瘤患者接受局部放疗或局部放疗后加用COP方案治疗。化疗的加入对原发性淋巴结疾病没有明显影响。横膈以下肠道出现的结外疾病似乎受到放疗的不利影响，因为放疗必然会持续数周，从而延迟了化疗的使用。头颈部区域出现的结外疾病在约80%的患者中得到控制，常规使用预防性联合化疗对患者没有益处。
